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SchizophreniaIn an attempt to better understand themolecularmechanismof action of the antipsychotic lead LASSBio-579 and
of its mainmetabolite LQFM 037, the aim of this workwas to evaluate their intrinsic activity and binding kinetics
at the dopamine D2 receptor. In transfected HEK cells expressing the D2L receptor under an inducible promoter,
LASSBio-579 and LQFM 037, but not clozapine, behaved as weak partial agonists in [35S]-GTPγS binding assays
performed in optimized conditions previously shown to evidence the partial agonist proﬁle of aripiprazole. Be-
sides, data obtained in radioligand competition assays on rat striatal membranes suggested a rapid association
to and dissociation from the D2-like receptors. Using the kinetic rate index based on the strategy of the dual-
point competition association assay, we showed that our compounds share a similar kinetic proﬁle with cloza-
pine, distinct from the typical antipsychotic haloperidol. These two characteristics could contribute to the
atypical-like proﬁle observed after administration of LASSBio-579 to rodents, in models of positive and negative
symptoms of schizophrenia.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
According to the World Health Organization (WHO, 2014), schizo-
phrenia is a “severe mental disorder, characterized by profound disrup-
tions in thinking, affecting language, perception, and the sense of self”,
being characterized by positive and negative symptoms and cognitive
dysfunction. The pharmacological treatment of schizophrenia essential-
ly relies on drugs classiﬁed as typical and atypical antipsychotics. Typi-
cal antipsychotics, as haloperidol and chlorpromazine, are effective
against positive symptoms but often cause extrapyramidal side effects
and prolactin elevation (Ginovart and Kapur, 2012). The atypical anti-
psychotics (e.g. clozapine and risperidone), are also effective against
positive symptoms, somewhat more efﬁcacious for improving negative
symptoms and are associated with lower incidence of extrapyramidaletamine; GPCR, G protein–
ethyl-D-glucamine.
omédicas, UFRJ, Avenida Carlos
J1-17, CEP 21941-912 Ilha dosymptoms (EPS) (Leucht et al., 2009). Nevertheless, metabolic distur-
bances including weight gain and hyperlipidemia are major side effects
associated with atypical antipsychotics, although a large heterogeneity
exists within this class of molecules (Leucht et al., 2009; Patel et al.,
2014; Raedler, 2010). With respect to their mechanism of action, typical
and atypical antipsychotics also differ in their receptor binding proﬁles:
typical antipsychotics are considered as relatively pure antagonists of
the D2 receptors, whereas the atypical antipsychotics are usually multi-
target drugs acting at the D2 receptor but also at serotonin, cholinergic
and/or adrenergic receptors (Ginovart and Kapur, 2012; Roth et al.,
2004). In fact, the mechanism supporting their atypical proﬁle has not
been unveiled, even for clozapine, and could have different back-
grounds as suggested by several concepts that have been proposed:
dual antagonism at 5-HT2A and D2 receptors (Meltzer, 1989), selective
blockade of D4 receptors (clozapine), partial agonism at 5-HT1A receptors
(Newman-Tancredi and Kleven, 2011), rapid dissociation (Seeman,
2002) and/or partial agonism (Strange, 2008) at D2 receptors and inhibi-
tion of glycogen synthase kinase-3 (Beaulieu et al., 2009). Focusing on the
D2 receptor, the “fast-off” theory proposes that atypical drugs are loosely
bound and rapidly released from D2 receptors in the synapse explaining
their lower propensity to induce EPS and hyperprolactinemia (Ginovart
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et al., 2012). Another property that could explain the atypicality of
some antipsychotic is a partial agonism at the D2 receptor. A weak but
signiﬁcant positive intrinsic activity could reduce the occurrence of extra-
pyramidal side effects commonly assigned to persistent blockade of
striatal D2 receptors,without decreasing the capacity of reducing the pos-
itive symptoms due to a hyperdopaminergic drive in the mesolimbic
pathway (Guo et al., 2013; Kapur and Seeman, 2000; Seeman, 2002).
We previously described (Menegatti et al., 2003) the synthesis of
LASSBio-579 (1-[1-(4-chlorophenyl)-1H-4pyrazolylmethyl] phenyl-
hexahydropiperazine), that has been elected as a new atypical antipsy-
chotic lead compound based on in vitro and in vivo assays classically
used in antipsychotic drug discovery programs. Brieﬂy, oral administra-
tion of LASSBio-579 in mice inhibited the apomorphine-induced
climbing, ketamine-induced hyperlocomotion and deﬁcit of prepulse
inhibition of acoustic startle reﬂex induced by apomorphine, (±)-DOI
and ketamine (Neves et al., 2013). Our binding studies deﬁned
LASSBio-579 as a moderate afﬁnity ligand of D2-like/D4/5-HT1A recep-
tors (Ki values around 0.2–0.4 μM) with low afﬁnity for the 5-HT2A re-
ceptor (Ki around 7 μM) and other receptors putatively involved in
atypicality (Neves et al., 2010; Pompeu et al., 2013). We also identiﬁed
and synthesized the main metabolite of LASSBio-579 in rats as its p-
hydroxylated derivative (LQFM 037), and reported its binding to the
D2 and D4 receptors at submicromolar concentrations, indicating that
it could participate to the antipsychotic-like effects observed after admin-
istration of the parent compound (Gomes et al., 2013). All these previous
in vitro and in vivo promising preclinical results suggest that LASSBio-579
could have antipsychotic effects albeit translating basic research into via-
ble products is particularly difﬁcult in Schizophrenia (Abbott, 2010).
In an attempt to better understand the molecular mechanism of ac-
tion of LASSBio-579 and of itsmainmetabolite, the aim of this workwas
to test the hypothesis of partial agonism and fast-off binding at the do-
pamine D2 receptor.
2. Materials and methods
2.1. Radioligands and drugs
Cell culture medium (Dulbecco's Modiﬁed Eagle Medium) and G418
(50 mg/mL Stock) were from Gibco-Invitrogen (Merelbeke, Belgium).
Bovine serum was purchased from Thermoscientiﬁc (Tournai, Belgium).
Guanosine 5′-O-(γ-[35S]thiotriphosphate) ([35S]GTPγS) (speciﬁc activity
of at least 1250 Ci mmol−1) and [3H]-YM-09151-2 (82.7 Ci/mmol) were
purchased fromNewEngland Nuclear Life Science Products, PerkinElmer,
USA. All drugs were of high quality. 1-[1-(4-Chlorophenyl)-1H-4-
pyrazolylmethyl]-4-phenylhexahydropyperazine (LASSBio-579) and its
p-hydroxylated metabolite (LQFM 037) were obtained as described else-
where (Gomes et al., 2013; Menegatti et al., 2003). The test substances
and (-)-sulpiride were dissolved in DMSO to obtain stock solutions. Sub-
sequent dilutionswere prepared in incubation buffer orwater. At theﬁnal
concentration used (0.2% at most), DMSO had no effect in our assays.
2.2. Transfected cells and inducible expression
The establishment of an inducible expression system of the D2L re-
ceptor has been previously described in details (Koener et al., 2012).
Cellswere routinelymaintained inDulbecco'smodiﬁed Eagle'smedium,
supplementedwith fetal bovine serum (10% v/v), 1% penicillin–strepto-
mycin (Invitrogen), G418 (250 μg/mL) and hygromycin B (50 μg/mL), at
37 °C in 5% CO2. For the [35S]-GTPγS binding studies, the cells were plat-
ed in 175 cm2 ﬂask.When approaching conﬂuency, the antibiotics were
removed and the cultured medium was supplemented with doxycy-
cline (2 μg/mL) for 48 h and NaBu (5 mM) for 24 h in order to induce
a robust expression and high density of the D2L receptors before har-
vesting the cells.2.3. Membrane preparations
For [35S]-GTPγS binding assays, conﬂuent HeLa cells expressing the
D2L receptor grown with or without (control) doxycycline and NaBu
were washed and scraped on ice from the culture ﬂasks with cold phos-
phate buffered saline (PBS). The cell membranes were prepared as pre-
viously described (Koener et al., 2012) and the protein concentration
was determined by the method of Bradford (1976).
For radioligand binding assays (see 2.5.), striatum of adult male
Wistar rats were homogenized and centrifuged as previously described
(Pompeu et al., 2013). The pellet was resuspended in 20 volumes of
buffer and incubated at 37 °C during 10 min for removal of endogenous
neurotransmitters. This suspension was cooled on ice and ultracentrifuged
twice at 48,000 g for 20 min at 4 °C. The ﬁnal pellet was resuspended and
stored in liquid nitrogen until use. The protein concentration was deter-
mined by the method of Lowry et al., 1951.
2.4. [35S]-GTPγS binding assay
The binding experiments were performed using a binding buffer
containing 50 mM Tris–HCl (pH 7.4), 1 mM EDTA, 5 mM MgCl2,
150 mM NaCl, 10 μM GDP and 1 mM dithiotreitol. When indicated,
NaCl was substituted by 100 mM NMDG. The experiment was carried
out in deep 96-well plates. Each well contained 30 μg protein, resus-
pended in a ﬁnal volume of 500 μL. In all experiments, [35S]GTPγS at
the ﬁnal concentration of 0.1 nMwas added to each well before initiat-
ing the binding by addition of the membrane suspension. The non-
speciﬁc bindingwasmeasured in the presence of 100 μMGpp(NH)p. In-
cubation was performed at 30 °C for 40 min and terminated by the ad-
dition of 1 mL ice-cold washing buffer (Tris–HCl, pH 7.4, 1 mM EDTA,
5mMMgCl2, with either 150mMNaCl, or 100mMNMDG). The suspen-
sionwas immediately ﬁltered through 96-well plate adapted-GF/B glass
ﬁber ﬁlters and the ﬁlters processed as previously described (Koener
et al., 2012).
2.5. Competition association assay
Binding kinetics of haloperidol, clozapine, LASSBio-579 and LQFM
037 were evaluated using the competition association assay
(Motulsky and Mahan, 1983) with a single concentration of the unla-
beled compounds around their Ki values. The assay was initiated by
adding 50 μg of striatal membranes in a ﬁnal volume of 500 μL, under
yellow light in a buffer containing Tris–HCl (pH 7.4), NaCl 120 mM,
KCl 5 mM, MgCl2 5 mM, CaCl2 1.5 mM, EDTA 1 mM with 0.2 nM [3H]-
YM-09151-2 at 37 °C in the absence or presence of unlabeled com-
pounds. The non-speciﬁc binding was estimated using 30 μM (-)-
sulpiride. At different time points, samples were rapidly diluted with
3 × 4mL Tris–HCl 5 mM (pH 7.4) and immediately ﬁltered under vacu-
um on glass ﬁber ﬁlters (GMF 3, Filtrak, Germany). Filters were then
dried, immersed in a scintillationmixture and the radioactivity counted
(Pompeu et al., 2013).
2.6. Data analysis
All experimental data were analyzed using GraphPad Prism 5.0
(GraphPad Software, Inc., CA, USA). All values are means of at least
three independent experiments performed in triplicate. For the [35S]-
GTPγS binding, data were analyzed by non-linear regression using the
classical equations for simple concentration-effect curves and competi-
tion binding assays. For the competition association assay with [3H]-
YM-09151-2, data were ﬁtted using the model of one-phase exponen-
tial association in order to obtain the half-life values and the maximum
binding at equilibrium. For calculation of the kinetic rate index (Guo
et al., 2013) we divided the ﬁtted binding at 5 min (Bt1) by the value
at 60 min (Bt2), in each experiment. Differences of half-life and kinetic
Table 1
Maximum effect (values in % stimulation of the [35S]-GTPγS binding, considering dopa-
mine as 100% stimulation) of different compounds at the D2 receptor tested in the two
binding buffers (NaCl and NMDG). Mean values from two separate experiments per-
formed in quadruplicate are shown.
Compound Emax (% of stimulation relative to
dopamine)
NaCl buffer NMDG buffer
Dopamine 100 μM 100 (310a) 100 (261a)
Apomorphine 10 μM 63.5 84
3-PPP 100 μM 12.5 65
Aripiprazole 1 μM 1.42 20.7
LASSBio-579 10 μM 0.9 14
LQFM 037 10 μM 0 12.5
Clozapine 10 μM −2.35 −7.1
Domperidone 0.1 μM −3.14 −6.7
a % stimulation of dopamine, in absolute values (mean value of two separate experi-
ments performed in quadruplicate).
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by Newman–Keuls post-hoc test.
3. Results
3.1. Quantitative evaluation of the intrinsic activity of LASSBio-579, LQFM
037 and clozapine at the D2L receptor
The intrinsic activity of clozapine and our compounds at the D2L re-
ceptor was estimated using the classical [35S]-GTPγS binding assay in
membrane of HELA cells expressing the mouse D2L receptor. In a con-
ventional buffer containing NaCl, LASSBio-579 and LQFM 037 elicited
a modest increase in the speciﬁc [35S]-GTPγS binding, with Emax values
of 14±3.1% and 10.4±4.9%, respectively, while clozapine had no effect
(Fig. 1). On the other hand, in a buffer where NaCl was replaced by
NMDG (to eliminate Na+ ions while maintaining the osmolarity),
LASSBio-579 and LQFM 037 clearly stimulated [35S]-GTPγS binding in
a concentration-dependent manner, with Emax values of 34 ± 2.1%
(LASSBio-579) and 19.4 ± 2.1% (LQFM 037) (Fig. 1). Even in these
more favorable experimental conditions, clozapine was not able to sig-
niﬁcantly promote the speciﬁc binding of [35S]-GTPγS.
In order to quantitatively evaluate the efﬁcacy of our compounds,we
compared their maximal capacity to stimulate [35S]-GTPγS to the ones
of full agonist, partial agonists with different intrinsic activity and the
reference antagonist domperidone (Table 1). For this purpose, we
used each drug at a single high concentration, sufﬁcient to approach
the maximal effect. Replacing NaCl by NMDG did not increase the max-
imum effect of dopamine and apomorphine, two agonists with high ef-
ﬁcacy (high Emax). On the other hand, the maximum effect of the weak
partial agonists was increased considerably in the absence of Na+ ions,
as observed for 3-PPP (Emax increased approximately 5 times) (Table 1).
In the case of aripiprazole, which is a low efﬁcacy partial agonist, an in-
crease in [35S]-GTPγS binding was only detected in the NMDG contain-
ing buffer. As shown in Table 1, LASSBio-579 and LQFM 037 shared this
proﬁle but their effect was smaller than that observed with aripiprazole
(Emax = 36.4% and 32.6% of stimulation above the basal level, respec-
tively, vs 54% of stimulation for aripiprazole). On the other hand,
domperidone and clozapine did not stimulate [35S]-GTPγS binding, nei-
ther in the NMDG buffer, as expected for (neutral) antagonists of the D2
receptor (Table 1). Taking advantage of the inducible expression system
in our model of transfected cells, we also tested the activity of LASSBio-
579 and LQFM 037 in cells not exposed to doxycycline and NaBu. As ex-
pected, LASSBio-579 and LQFM037 did not change [35S]-GTPγS binding,
conﬁrming that both compounds promoted nucleotide binding through
activation of the D2L receptor in these cells (data not shown).
Classically, partial agonism is fully characterized when demonstrat-
ing that a drug is able to produce an effect by itself and to partially re-
duce the effect of a full agonist. In our experimental conditions,
antagonism at the D2L receptor was validated using domperidone. In-
deed, domperidone fully blocked the effect of dopamine (1 μM) in aNaCl buffer
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Fig. 1. Effect of LASSBio-579, LQFM 037 and clozapine on [35S]-GTPγS binding in the NaCl a
experiments.concentration-dependentmanner in the two buffers, with a small right-
ward shift of the concentration-curve when tested in the NMDG buffer
that favors the stimulatory effect of dopamine (Fig. 2B). Using the same
protocol in the NaCl containing buffer, LASSBio-579 and LQFM 037 an-
tagonized the stimulation of [35S]-GTPγS binding by dopamine 1 μM
in a concentration-dependent manner, with IC50 values of 1.8 μM (95%
CI: 1.31–2.38 μM) for LASSBio-579 and 0.8 μM (95% CI: 0.29–2.1 μM)
for LQFM 037 (Fig. 2C). However, the inhibition was not complete, re-
ducing the response to 25 ± 4% (LASSBio-579) and 11 ± 8% (LQFM
037) of the stimulatory effect of dopamine, even at the highest concen-
trations of the compounds. This pattern is consistent with the fact that
LASSBio-579 and LQFM 037 are partial agonists and in good accordance
with their respective levels of intrinsic activity reported in Table 1. In the
NMDG containing buffer, which favors the stimulatory effect not only of
dopamine but especially of the weak partial agonists, the antagonism
exerted by both LASSBio-579 and LQFM 037 was less obvious, with a
shift to the right of the inhibition curves. For this reason, it was not pos-
sible to obtain complete curves with these compounds, due to the lack
of solubility at higher concentrations. At the highest concentration test-
ed of the compounds (30 μM), thedopamine responsewasdecreased by
approximately 35–38% (Fig. 2D). Together, these results suggest that
like aripiprazole and unlike clozapine, LASSBio-579 and LQFM 037 can
be considered as weak partial agonists of the D2L receptor.
3.2. Binding kinetics of LASSBio-579, LQFM 037, clozapine and haloperidol
to the D2-like receptors
Based on the “fast-off” theory for explaining the atypicality of anti-
psychotic action (Kapur and Seeman, 2000; see introduction), we decid-
ed to compare the kinetics of binding of our compounds with those of
haloperidol and clozapine, as controls for typical and atypical antipsy-
chotics, respectively. As radiolabeled derivatives of LASSBio-579 and NMDG buffer
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Fig. 2. Effect of increasing concentrations of domperidone, LASSBio-579 and LQFM 037 on the binding of [35S]-GTPγS in the presence of a ﬁxed concentration of dopamine (1 μM) in the
NaCl and NMDG buffer. Data are expressed as the means curves from three independent experiments.
4 T.E.T. Pompeu et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 62 (2015) 1–6LQFM 037 are not available, we decided to adapt the competition asso-
ciation assay described originally by Motulsky andMahan (1983) using
[3H]-YM09151-2, a high-afﬁnity and selective antagonist ligand for the
dopamine D2 receptor. Thus, the kinetic of [3H]-YM09151-2 binding to
rat striatal D2 receptors was determined in the absence and presence
of a single concentration of the unlabeled competitors, chosen in order
to achieve similar inhibition at equilibrium.
Fig. 3 shows the association of the reference radioligand determined
in three to seven independent experiments and the curves ﬁtted0 10 20 30 40 50 60
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Fig. 3. Kinetics of [3H]-YM09151-2 binding to rat striatal D2 receptors in the absence and prese
three to seven independent experiments. The curves were ﬁtted according to the model of oneaccording to the model of a one phase exponential association. As ex-
pected, the time to reach equilibrium (here estimated quantitatively
by the half-life (t1/2) was increased in the presence of the competitors
(Table 2). In addition, a clear differencewas observed between haloper-
idol and clozapine, since clozapine increasedmore than twice the t1/2 of
[3H]-YM09151-2 binding when compared to the t1/2 measured in the
presence of haloperidol (p b 0.001).
As the concentrations of the competitors were roughly equivalent in
terms of effect at equilibrium (% inhibition: 22–39%, see Table 2), the0 10 20 30 40 50 60
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nce of competitors. Data expressed as percent of the control at 60min are the means from
phase exponential association (see Materials and methods).
Table 2
Kinetic parameters from the competition association assay: half-life time (t1/2) and kinetic
rate index.
Compound
(concentration)
% Inhibition (at
equilibrium)
Half-life (min) Kinetic rate index
(Bt1/Bt2)
Control – 5.10 ± 0.27 0.510 ± 0.020
Haloperidol (5 nM) 38.6 ± 6.4 7.70 ± 0.63 0.360 ± 0.024**
Clozapine (0.3 μM) 26.5 ± 2.3 12.6 ± 0.96***# 0.250 ± 0.015***#
LASSBio-579 (0.3 μM) 33.2 ± 3.5 16.2 ± 2.3***### 0.230 ± 0.028***#
LQFM 037 (0.3 μM) 22.3 ± 1.6 17.9 ± 1.8***### 0.190 ± 0.012***#
The kinetic rate indexwas obtained dividing the binding value calculated at 5min (Bt1) by
the value at 60 min (Bt2), as described in details in the Materials and methods. Data are
expressed as mean ± SEM from three to seven independent experiments. * vs control; #
vs haloperidol; * or #; ** or ##; *** or ###: p b 0.05; 0.01; 0.001, one way ANOVA followed
by Newman–Keuls post-hoc test.
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of the unlabeled competitors, with higher values indicating rapid asso-
ciation and dissociation.With respect to their effect on [3H]-YM09151-2
binding, our compounds showed great similarity with clozapine, lead-
ing to even higher values of t1/2, thus very differently from the typical
antagonist haloperidol (Table 2). Based on the method proposed by
Guo et al. (2013) to distinguish compounds with rapid or slow dissoci-
ation from the target, we also measured a kinetic rate index. Table 2
shows that the values of this index, obtained by calculating the ratio
of binding values measured at 5 min and 60 min, were signiﬁcantly
lower with clozapine than with haloperidol, again supporting a more
rapid association and dissociation. This second approach in analyzing
the binding kinetics of unlabeled ligands also indicated clearly that
LASSBio-579 and LQFM 037 were comparable to clozapine but not to
haloperidol for their binding to the D2 receptor (Table 2).
4. Discussion
In the present study, we addressed the question of the molecular
mechanism of action of LASSBio-579, a lead compound that we previ-
ously reported as having atypical-like properties in rodent models of
schizophrenia, and of its main metabolite (LQFM 037). We decided to
focus here on two characteristics related to theD2 receptors, the key tar-
get of all antipsychotics used clinically, that could contribute, at least
partially, to their reported atypical-like proﬁle in rats.
4.1. Intrinsic activity at the D2 receptor
Firstly, we investigated the intrinsic activity of LASSBio-579 (and of
its mainmetabolite, LQFM 037) at the D2 receptor based on the hypoth-
esis that partial agonism at this receptor could balance the hyperactive
dopaminergic drive in the mesolimbic pathway and the hypoactive
drive in the mesocortical pathway, that are considered as hallmarks of
schizophrenia (Ginovart and Kapur, 2012; Tamminga, 2002). Moreover,
by avoiding excessive blockade of nigrostriatal D2 receptors, a partial ag-
onist would have a lower propensity to cause EPS and prolactin eleva-
tion (Ginovart and Kapur, 2012; Tamminga, 2002). This idea gained
force with the demonstration that aripiprazole has a distinct mecha-
nism of action (sometimes even elected as a third generation antipsy-
chotic) based on reports indicating that it behaves as a low efﬁcacy
partial agonist at the D2 receptor, effective against positive and negative
symptoms without causing EPS and hyperprolactinemia (Burris et al.,
2002). However, the type of assay and experimental conditions are cru-
cial in order to characterize compounds endowedwith low intrinsic ac-
tivity (Jordan et al., 2007; Lin et al., 2006) as also conﬁrmed by our
previous work with aripiprazole (Koener et al., 2012). Using the same
protocol, we indeed evidenced an increase in [35S]GTPγS binding with
aripiprazole only when using cells with a considerably high expression
of the D2 receptors and when Na+ ions were substituted by NMDG in
the buffer. These results are in accordance with the literature since it
is known that sodium ions disfavor the formation of the ternarycomplex of GPCRs and that the replacement of Na+ ions by NMDG in-
creases the sensitivity for detecting partial agonists with low efﬁcacy
(Lin et al., 2006). The same pattern was observed with our compounds,
so that they can also be considered asweak partial agonists of the D2 re-
ceptor. However, one has to be cautious when considering the clinical
relevance of this property since some authors reported that the partial
agonism of aripiprazole depended on the cell-line and the pathway an-
alyzed, suggesting that the originality of aripiprazole could be due to a
functional selective proﬁle at the D2 receptor (Shapiro et al., 2003;
Urban et al., 2007).
4.2. Kinetics of binding at the D2 receptor
Drug-target residence time, a concept coined by Copeland
(Copeland et al., 2006) and in consonance with earlier work on the
bindingmechanisms of drugs (Swinney, 2004), has gainedmuch atten-
tion in recent drug discovery literature. This concept was initially intro-
duced to point out the advantages of long residence timewith respect to
duration of effect and target selectivity. On the contrary, in accordance
with the “fast-off” theory of atypical antipsychotic action, a loose bind-
ing to the D2 receptor would be beneﬁcial thanks to a rapid dissociation
from the receptor and a lower propensity to induce on-target toxicity
such as EPS (Guo et al., 2013; Seeman, 2014). In the case of antipsy-
chotics, a correlation was revealed between high afﬁnity and in vitro
low-dissociation rate (direct correlation between Ki and koff) for a series
of drugs (Kapur and Seeman, 2000). In these experiments, clozapine,
themore efﬁcacious atypical antipsychotic, dissociatedmuchmore rap-
idly (koff about 80 times higher) than haloperidol, used here as reference
typical antipsychotic. Although such low dissociation has been con-
ﬁrmed in recent works, especially for clozapine, quetiapine and
olanzapine (Seeman, 2014; Vauquelin et al., 2012), not all published
studies support the “fast-off” theory of atypicality. Sahlholm et al.
(2014), for instance, reported that recovery from clozapine and
amisulpride antagonism was less than two fold faster than from chlor-
promazine in a functional assay characterized by the presence of contin-
uous buffer ﬂow and of dopamine competition, supposed to prevent
antagonist rebinding that can occur in binding dissociation studies
(Vauquelin et al., 2012). However, this kind of highly effective washout
of antagonist could also be far from the in vivo situation at the synapse
level, where rebinding could occur and contribute to the residence time
of the antagonist at the receptor. In order to compare our drugs, not
available as radiolabeled ligands, to haloperidol and clozapine, we
adapted the competition kinetic assay proposed by Motulsky and
Mahan (1983) and measured the binding of [3H]-YM09151-2 at 11
time points, in the absence and presence of a single concentration of
the unlabeled competitors. The half-lives of binding indicated that our
compounds inﬂuenced the radioligand binding kinetics similarly to clo-
zapine but differently from haloperidol. Of note, this protocol was prov-
en useful to discriminate clozapine and haloperidol, with statistical
power, and that a higher t1/2 (clozapine N haloperidol) was expected
for a drug dissociating more rapidly.
We also used an alternative approach to compare quantitatively the
binding kinetics of our unlabeled ligands, based on the strategy of the
dual-point competition association validated by Guo et al. (2013) for
use in high-throughput screening aiming the discrimination of slowly
and rapidly dissociating compounds at the adenosine A1A receptor.
Here too, using the kinetic rate index, our results clearly indicated that
our compounds share a similar binding kinetic proﬁle with clozapine,
signiﬁcantly different from the one of haloperidol. Noteworthy, a limita-
tion of our assay was the fact that the radioligand commonly used for
binding to the D2-like receptors, [3H]-YM09151-2 (nemonapride)
shows a very slow dissociation rate (koff = 0.002 min−1), much lower
than both the rapidly (clozapine: koff = 1.39 min−1) and slowly (halo-
peridol: koff = 0.017 min−1) dissociating drugs (Kapur and Seeman,
2000). This explains why when using haloperidol as a slowly dissociat-
ing drugwe failed to observe the “overshoot” of the time course curve of
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et al., 2014). In fact, as explained by Motulsky and Mahan (1983,
Fig. 3A), the association curve of the radioligand will consist of two
phases, starting with a typical “overshoot” and then a decline until a
new equilibrium is reached only if the competitor dissociates faster
from its target than the radioligand.
4.3. Mechanism of atypicality
A priori, the most classical hypothesis for atypicality, higher afﬁnity
for 5-HT2A than for D2 receptors (Meltzer, 1989), could not apply to
our compounds since they have an inverted selectivity with about 16–
18 times more afﬁnity for the D2-like receptors than for the 5-HT2A re-
ceptors (Gomes et al., 2013). Indeed the D2/5-HT2A Ki ratios obtained
with LASSBio-579 and LQFM037 in vitro (0.056 and 0.064, respectively)
were about 100 times lower thanwith clozapine (6.5), according to pre-
vious data (Gomes et al., 2013). Furthermore, there are many excep-
tions to this concept of 5-HT2A/D2 relative selectivity for explaining
atypicality (Seeman, 2014) as amisulpride, for example, is considered
as a very selective antagonist of the D2–D3 receptors lacking afﬁnity
for the 5-HT2A receptors (Natesan et al., 2008). On the other hand, we
cannot rule out a contribution of 5-HT2A antagonism in vivo, for two rea-
sons: 1. We previously reported that LASSBio-579 reduced the number
of head-twitches and ear-scratches induced inmice by (±)DOI, a selec-
tive 5-HT2 agonist (Neves et al., 2008). 2. It has been shown that
brexipiprazole binds with high afﬁnity to both rat D2 and 5-HT2A recep-
tors in vivo albeit it has a D2/5-HT2A Ki ratio similar to LASSBio-579
(0.092) in vitro (Maeda et al., 2014).
5. Conclusion
LASSBio-579 and its main metabolite (LQMF 037) share with
aripiprazole, but not clozapine, the property to behave as weak partial
agonists at the D2L receptor, at least in deﬁned experimental conditions.
Our compounds also have a binding kinetic proﬁle similar to clozapine
in vitro, indicating a rapid dissociation from the target (D2) receptor,
at variance with haloperidol. These two characteristics could contribute
to the atypical-like proﬁle observed after administration of LASSBio-579
to rodents, in different models of positive and negative symptoms.
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